Pharma BD Deal Intelligence

Mylan N.V. / Meda AB

2016 · Acquisition/Merger · $9.9B · Complete

The Street Said

Positive — critic reaction at announcement

History Says

Mixed — partial payoff, real shortfalls

CALLED IT — OFF BY 10

Full analysis, sources & comparables →

The coverage arc

Feb 16, 2016 In-Pharma Technologist Bearish

Analysts viewed the Mylan-Meda deal as part of relentless generics consolidation, but questioned whether scale alone could overcome pricing pressures squeezing…

Aug 05, 2016 Mylan Completes Acquisition of Meda - PR Newswire Bullish

Mylan completed its recommended public offer to shareholders of Meda Aktiebolag, creating a diversified global pharmaceutical leader with strong presence…

Jan 23, 2017 GEN Neutral

Mylan acquired Meda for $9.9B to expand branded and generic drug portfolio.

Source summaries from our enrichment pipeline; follow links for originals.

All 8 sources with sentiment breakdown →

Mylan acquired Meda for $9.9B to expand branded and generic drug portfolio.

Key facts

Announced Feb 10, 2016
Closed Aug 05, 2016
Deal value $9.9B
Deal type Acquisition/Merger
Key assets azelastine/fluticasone propionate (Dymista), Branded generics / specialty portfolio

Related deals — scored

Deal	Year	Value	Outcome
Mylan N.V. / Meda AB (this deal)	2016	$9.9B	53
Mylan N.V. / Upjohn Inc. (Pfizer)	2019	$12.0B	44
Mylan N.V. / Renaissance Acquisition Holdings, LLC (topicals business)	2016	$1.0B	40
Mylan N.V. / Novartis AG (TOBI franchise)	2018	$463M	38
Mylan N.V. / Perrigo Company plc	2015	$26.0B	—
AbbVie Inc. / Boehringer Ingelheim GmbH	2016	$2.2B	95
Abbott Laboratories / Alere Inc.	2016	$5.8B	95

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals

More: 2016 deals · Mylan N.V. deals